Ignite Creation Date:
2024-05-05 @ 11:42 AM
Last Modification Date:
2024-10-26 @ 9:12 AM
Study NCT ID:
NCT00116792
Status:
UNKNOWN
Last Update Posted:
2007-05-17
First Post:
2005-06-30
Brief Title:
PROVIDENCEPrevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With Coronary Lesions
Sponsor:
Gold Herman K MD
Organization:
Gold Herman K MD
Study Overview
Official Title:
PROVIDENCE Prevention of Restenosis With Oral Rosiglitazone and the Vision Stent in Diabetics With de Novo Coronary Lesions
Status:
UNKNOWN
Status Verified Date:
2007-05
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
We hypothesize that the combination of the thin-strut MULTI-LINK ie VISIONtm andor MINI-VISIONtm stent and pharmacologic therapy with the oral PPAR-gamma agonist rosiglitazone will significantly reduce restenosis after intracoronary stenting in type 2 diabetic patients This approach would present a more effective and economical alternative to the use of drug-eluting stents to reduce stent restenosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None